Cargando…

Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report

Breast cancer (BC) with overexpression of human epidermal growth factor receptor 2 (HER2) is closely associated with an elevated risk of multiple distant metastases and unfavorable prognosis. Disitamab Vedotin (RC48) is a newly developed antibody-drug conjugate targeting HER2, which is comprised of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qifeng, He, Lina, Luo, Jing, Jin, Wen, Xu, Yingchun, Wang, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404700/
https://www.ncbi.nlm.nih.gov/pubmed/36039062
http://dx.doi.org/10.3892/ol.2022.13459
_version_ 1784773696441810944
author Wu, Qifeng
He, Lina
Luo, Jing
Jin, Wen
Xu, Yingchun
Wang, Chen
author_facet Wu, Qifeng
He, Lina
Luo, Jing
Jin, Wen
Xu, Yingchun
Wang, Chen
author_sort Wu, Qifeng
collection PubMed
description Breast cancer (BC) with overexpression of human epidermal growth factor receptor 2 (HER2) is closely associated with an elevated risk of multiple distant metastases and unfavorable prognosis. Disitamab Vedotin (RC48) is a newly developed antibody-drug conjugate targeting HER2, which is comprised of hertuzumab coupled to monomethyl auristatin E via a cleavable linker. Pre-clinical studies indicated its strong anti-tumor activity in HER2-positive and low HER2 expression models of BC. The present study reported on the case of a 60-year-old postmenopausal female who suffered from fatigue and was diagnosed with a right-sided BC tumor. The diagnosis was stage IV (cT4N3M1) hormone receptor (HR)-positive and HER2-positive invasive ductal carcinoma with systemic metastases (brain included). The patient initially responded well to 26 cycles of the first-line anti-HER2 targeted therapy plus chemotherapy (trastuzumab+pertuzumab+nab-paclitaxel) combined with whole-brain radiotherapy. However, both extracranial and intracranial lesions achieved progressive disease (PD), which eventually occurred during 5 sequential cycles of maintenance therapy. Subsequently, 4 cycles of second-line treatment (trastuzumab + pyrotinib + capecitabin) were continued until the levels of blood tumor markers CEA, CA15-3 and CA125 were elevated, and systemic PD was able to be attained (the brain metastases were rated as stable disease). Finally, the patient received RC48 as the third-line therapy and achieved a durable and effective clinical response. To date, the patient has benefited from 12 cycles of RC48 without any severe adverse effects. The overall survival was >3 years. The present study showcased that RC48 was effective and tolerable for a patient with HR- and HER2-positive BMBC.
format Online
Article
Text
id pubmed-9404700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-94047002022-08-28 Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report Wu, Qifeng He, Lina Luo, Jing Jin, Wen Xu, Yingchun Wang, Chen Oncol Lett Articles Breast cancer (BC) with overexpression of human epidermal growth factor receptor 2 (HER2) is closely associated with an elevated risk of multiple distant metastases and unfavorable prognosis. Disitamab Vedotin (RC48) is a newly developed antibody-drug conjugate targeting HER2, which is comprised of hertuzumab coupled to monomethyl auristatin E via a cleavable linker. Pre-clinical studies indicated its strong anti-tumor activity in HER2-positive and low HER2 expression models of BC. The present study reported on the case of a 60-year-old postmenopausal female who suffered from fatigue and was diagnosed with a right-sided BC tumor. The diagnosis was stage IV (cT4N3M1) hormone receptor (HR)-positive and HER2-positive invasive ductal carcinoma with systemic metastases (brain included). The patient initially responded well to 26 cycles of the first-line anti-HER2 targeted therapy plus chemotherapy (trastuzumab+pertuzumab+nab-paclitaxel) combined with whole-brain radiotherapy. However, both extracranial and intracranial lesions achieved progressive disease (PD), which eventually occurred during 5 sequential cycles of maintenance therapy. Subsequently, 4 cycles of second-line treatment (trastuzumab + pyrotinib + capecitabin) were continued until the levels of blood tumor markers CEA, CA15-3 and CA125 were elevated, and systemic PD was able to be attained (the brain metastases were rated as stable disease). Finally, the patient received RC48 as the third-line therapy and achieved a durable and effective clinical response. To date, the patient has benefited from 12 cycles of RC48 without any severe adverse effects. The overall survival was >3 years. The present study showcased that RC48 was effective and tolerable for a patient with HR- and HER2-positive BMBC. D.A. Spandidos 2022-08-12 /pmc/articles/PMC9404700/ /pubmed/36039062 http://dx.doi.org/10.3892/ol.2022.13459 Text en Copyright: © Wu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wu, Qifeng
He, Lina
Luo, Jing
Jin, Wen
Xu, Yingchun
Wang, Chen
Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
title Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
title_full Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
title_fullStr Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
title_full_unstemmed Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
title_short Long-term remission under Disitamab Vedotin (RC48) in HR-positive/HER2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report
title_sort long-term remission under disitamab vedotin (rc48) in hr-positive/her2-positive metastatic breast cancer with brain meningeal, and bone marrow involvement: a case report
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404700/
https://www.ncbi.nlm.nih.gov/pubmed/36039062
http://dx.doi.org/10.3892/ol.2022.13459
work_keys_str_mv AT wuqifeng longtermremissionunderdisitamabvedotinrc48inhrpositiveher2positivemetastaticbreastcancerwithbrainmeningealandbonemarrowinvolvementacasereport
AT helina longtermremissionunderdisitamabvedotinrc48inhrpositiveher2positivemetastaticbreastcancerwithbrainmeningealandbonemarrowinvolvementacasereport
AT luojing longtermremissionunderdisitamabvedotinrc48inhrpositiveher2positivemetastaticbreastcancerwithbrainmeningealandbonemarrowinvolvementacasereport
AT jinwen longtermremissionunderdisitamabvedotinrc48inhrpositiveher2positivemetastaticbreastcancerwithbrainmeningealandbonemarrowinvolvementacasereport
AT xuyingchun longtermremissionunderdisitamabvedotinrc48inhrpositiveher2positivemetastaticbreastcancerwithbrainmeningealandbonemarrowinvolvementacasereport
AT wangchen longtermremissionunderdisitamabvedotinrc48inhrpositiveher2positivemetastaticbreastcancerwithbrainmeningealandbonemarrowinvolvementacasereport